Browse our anti-Natural Cytotoxicity Triggering Receptor 3 (NCR3) Antibodies

Human Natural Cytotoxicity Triggering Receptor 3 (NCR3) interaction partners

1. this paper shows that the decreased expression of activating receptor NKp30 on peripheral blood NK cells is positively associated with gastric cancer progression

2. Low NKp30 expression on NK cells is associated with Nasopharyngeal Carcinoma.

3. we propose NKp30 status as a simple and early prognostic biomarker that identifies intermediate-risk patients with poor prognosis who otherwise may not be identified with existing risk stratification systems.

4. Data indicate a sequence of events driven by tumour-derived prostaglandin D2 (PGD2) associated with engagement of the natural cytotoxicity triggering receptor 3 (NKp30)-B7H6 antigen (B7H6) pathway leading to significant group 2 innate lymphoid cells (ILC2s) activation and expansion.

5. NKp44 and NKp30 splice variants profiles are tissue/condition specific and demonstrate similarity between placenta and cancerous tissues.

6. Results found that rs2736191-C NCR3 carriers had a significant increased number of mild malaria episodes compared to the non-carriers. This SNP had a significantly increased promoter activity in NCR33 gene and involves a binding site for STAT4 and RUNX3.

7. findings show HIV reservoir size is dependent on the presence of a defined NK cell population with a specific transcriptional signature: high NCR (NKp46 and NKp30) and IFN-gamma inducibility upon NCR and cytokine receptor engagement

8. Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells

9. Data suggest that NK cells and NKp30 could play a role in Antisynthetase syndrome pathogenesis.

10. the stalk domains of NKp30 and NKp46, another NCR employing CD3zeta for signaling, were not exchangeable without drastic deficiencies in folding, plasma membrane targeting, and/or ligand-induced receptor signaling.

11. Age and CMV serostatus influence the expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated natural killer cells.

12. NKp30-B7-H6 interaction is a novel cell contact mechanism that mediates activation of Group 2 innate lymphoid cells and identifies a potential target for the development of novel therapeutics for atopic dermatitis and other atopic diseases.

13. Our results suggest that NKP30-B7-H6 interaction can aggravate hepatocyte damage, probably through up-regulation of IL-32 expression in hepatitis B virus-related acute-on-chronic liver failure

14. the interaction between NKp30 and B7-H6 may contribute to the fate of neuroblastoma patients

15. Suggest role for NKp30 isoforms in influencing liver damage and ensuing fibrosis in chronic hepatitis C infection.

16. show that in addition to NKG2D, human CEACAM1 can inhibit NK-cell activation via NKp30 or 2B4

17. Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasms.

18. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.

19. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.

20. NKp30 was required for natural killer cell-fungal conjugate formation, phosphatidylinositol 3-kinase (PI3K) signaling, and perforin release.

Chimpanzee Natural Cytotoxicity Triggering Receptor 3 (NCR3) interaction partners

1. phenotypic, molecular, and functional characterization for triggering molecules (NKp46, NKp30 NKp80, and NKG2D; in this AIDS-resistant species, relevant differences to human NK cells involve NKp80 and particularly NKp30